H.C. Wainwright Sticks to Their Buy Rating for MiMedx Group (MDXG)

In a report released today, Swayampakula Ramakanth from H.C. Wainwright maintained a Buy rating on MiMedx Group (MDXGResearch Report), with a price target of $8.00. The company’s shares closed yesterday at $2.76.

Ramakanth covers the Healthcare sector, focusing on stocks such as MiMedx Group, Rewalk Robotics, and X4 Pharmaceuticals. According to TipRanks, Ramakanth has an average return of -12.7% and a 29.16% success rate on recommended stocks.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for MiMedx Group with a $7.50 average price target.

See today’s best-performing stocks on TipRanks >>

MDXG market cap is currently $313.6M and has a P/E ratio of -11.09.

Based on the recent corporate insider activity of 39 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of MDXG in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

MiMedx Group, Inc. is an advanced wound care and an emerging therapeutic biologics company. It engages in developing and distributing human placental tissue allografts with patent-protected processes for multiple sectors of healthcare. The company processes the human placental tissue utilizing its proprietary PURION process methodology, among other processes, to produce allografts by employing aseptic processing techniques in addition to terminal sterilization. MiMedx Group was founded on July 30, 1985 and is headquartered in Marietta, GA.

Read More on MDXG:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More